In an exchange filing, the company said the approval covers Everolimus Tablets for Oral Suspension in 2 mg, 3 mg and 5 mg ...

BENGALURU, India and BRIDGEWATER, N.J., Oct. 1, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON) ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully ...

These products are among the largest oncology biologics expected to lose exclusivity over the next five years.

Biocon Pharma, a subsidiary of Biocon Ltd, has received approval from the USFDA for its generic Everolimus tablets to treat tuberous sclerosis complex. Available in 2 mg, 3 mg, and 5 mg, the drug is ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...

Investec has initiated coverage on Biocon Ltd. with a ‘buy’ rating and a target price of Rs 400, citing its strong positioning in the global biosimilars market and robust growth potential across its ...

HYDERABAD, Aug 11 (Reuters) - Indian biopharmaceutical company Biocon Ltd (BION.NS), opens new tab is planning to list its biosimilars business, a significant contributor to the company's total ...

Biocon Pharma receives USFDA approval for generic Everolimus tablets, used to treat tuberous sclerosis complex (TSC).

Shares of Steel Authority of India (SAIL) and Sammaan Capital are banned from F&O trading on 7 January 2026. Biocons subsidiary, Biocon Biologics will introduce three new oncology biosimilars at a US ...

MUMBAI (Reuters) - India's Biocon Ltd will retain milestone payments it received from Pfizer Inc as part of a deal that allowed the U.S. drugmaker to sell Biocon's insulin products globally, Biocon's ...